Data released earlier this month from a Phase 2 trial of OMS721, Omeros's most advanced clinical candidate, appear to have created some confusion in the market as the company's share price has fallen roughly 50% since the announcement, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The selloff is unwarranted, says the analyst, who reiterates a Buy rating on the shares with a $34 price target. He points out that the data were from a small trial that was not designed to deliver statistical significance or definitive evidence of efficacy. Further, the "data itself were encouraging, not discouraging, and there certainly was no evidence of any safety concern or toxicity issue that would have jeopardized OMS721's future development," Selvaraju writes.